Eli Lilly closer to securing FDA approval for Alzheimer’s drug [Video]

Eli Lilly (LLY) is one step closer to getting its new Alzheimer’s treatment approved by the Food and Drug Administration (FDA) after a panel voted to recommend its use. BMO Capital Markets Managing Director Evan Seigerman joins Market Domination to discuss how the drug will fit into the drug market.
Seigerman explains, “Investors have been hoping that the addition of another product, Lilly’s donanemab, could kind of help lift the entire market because having two products and basically three companies marketing the class should accelerate uptake.” He expects approval to be near-term but notes that the challenges of getting a diagnosis and the infrastructure involved could make it difficult for patients to access treatment.

About Yahoo Finance:

Yahoo Finance provides free stock ticker data, up-to-date news, portfolio management resources, comprehensive market data, advanced tools, and more information to help you manage your financial life.

– Get the latest news and data at finance.yahoo.com

– Download the Yahoo Finance app on Apple (https://apple.co/3Rten0R) or Android (https://bit.ly/3t8UnXO)

– Follow Yahoo Finance on social:

X: http://twitter.com/YahooFinance
Instagram: https://www.instagram.com/yahoofinance/?hl=en
TikTok: https://www.tiktok.com/@yahoofinance?lang=en
Facebook: https://www.facebook.com/yahoofinance/
LinkedIn: https://www.linkedin.com/company/yahoo-finance